Line 366: |
Line 366: |
| |PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751 | | |PMID:27090007; PMID:26061753; PMID:25263767 PMID:26061754; PMID:24335697; PMID:25664944;PMID:26061753; PMID:26941959; PMID:26824661 PMID:26061751 |
| |- | | |- |
| + | | |
| |Glioblastoma , grade IV, IDH mutant | | |Glioblastoma , grade IV, IDH mutant |
| |'''Gain:''' 1/1q, 6p<br> | | |'''Gain:''' 1/1q, 6p<br> |
Line 431: |
Line 432: |
| |- | | |- |
| | | | | |
| + | |Classic ependymoma (no WHO grade assigned) |
| + | |'''Gain:''' 1q, 5, 7, 9, 11, 18, 20<br> |
| + | '''Loss:''' 1p, 3, -6/6q, 9p, 13q, 17, 22 |
| + | |'''Loss:''' CDKN2A/CDKN2B (rare); NF2<br> |
| + | '''Mutation:''' NF2 (esp. in spinal tumors) |
| + | |Usually intracranial, spinal tumors (myxopapillary) are rare; 80% of pediatric tumors develop in posterior fossa (PF); Supratentorial tumors preferentially show monosomy 9; 1q gain is unfavorable prognostic indicator in PF tumors; spinal tumors associated with NF2 mutation (germline) |
| + | |PMID:25965575; PMID:22338015; PMID:28371821 |
| + | |- |
| + | | |
| + | |Subependymoma, WHO grade I <br> |
| + | (intracranial or spinal) |
| + | |Typically '''balanced genomes'''<br> |
| + | '''Loss:''' -6/6q in spinal tumors |
| + | |No diagnostic mutations |
| + | |Favorable prognosis |
| + | |WHO CNS Tumors (2016)<br> |
| + | PMID:21959044; PMID:21840481 |
| + | |- |
| + | | |
| + | |Myxopapillary ependymoma, WHO grade I (spinal) |
| + | |'''Aneuploidy:''' multiple chromosomes lost and gained |
| + | |'''Mutation:''' NF2 (including germline) in spinal tumors |
| + | |More common in adults |
| + | |PMID:25965575; PMCID:3991130; PMID:20425037 PMID:25957288; PMID:25965575; PMID:22516549 |
| + | |- |
| + | | |
| + | |Ependymoma, RELA fusion-positive, WHO grade II or III<br> |
| + | (intracranial) |
| + | |'''Gain:''' 1q<br> |
| + | '''Aneuploidy:''' multiple chromosomes lost and gained<br> |
| + | '''Chromothripsis:''' chromosome 11 (70% of supratentorial tumors) |
| + | |'''Fusion:''' c11orf95-RELA (supratentorial tumors)<br> |
| + | '''Loss:''' CDKN2A/B (may help distinguish from other supratentorial ependymomas) |
| + | |Unfavorable prognosis |
| + | |PMID:25965575; PMID:24553141; PMID:28371821 |
| + | |- |
| | | | | |
| + | |Anaplastic ependymoma (no WHO grade assigned; intracranial or spinal) |
| + | |'''Epigenetic studies''' suggest range of abnormalities: balanced or unbalanced genomes |
| + | |'''Mutation:''' NF2 (including germline) in spinal tumors<br> |
| + | '''Fusion:''' RELA fusions, YAP1 fusions can correspond to anaplastic histology |
| + | |Mostly intracranial tumors, rarely in spinal cord |
| + | |PMID: 25965575; PMID:27022130 |